Last reviewed: June 16, 2026

Last updated: June 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide and other GLP-1 receptor agonists have transformed weight loss treatment for millions, but pregnancy raises important safety questions. Current clinical guidance advises discontinuing semaglutide before conception and throughout pregnancy, though animal studies have not shown direct fetal harm. Understanding the evidence helps you make informed decisions about timing, alternatives, and personalized weight management.

Why Semaglutide Is Not Recommended During Pregnancy

Semaglutide received FDA approval for weight loss in 2021, yet regulatory agencies have not cleared it for use in pregnant patients. The primary reason is the absence of large, randomized human trials in pregnancy—a standard requirement for any medication given to expectant mothers. Animal reproduction studies showed no direct birth defects at comparable doses, but this evidence alone does not guarantee safety in human pregnancies, which involve complex metabolic and hormonal changes.

Pregnancy itself alters how the body processes medications, glucose regulation, and nutrient absorption. GLP-1 receptor agonists slow gastric emptying and reduce appetite, which could theoretically affect maternal nutrition or fetal growth if continued during pregnancy. Most obstetricians and weight loss specialists recommend pausing semaglutide at least three months before attempting conception to allow the medication to clear your system and establish stable baseline blood sugar control.

If you became pregnant while taking semaglutide, stopping immediately is the standard recommendation. A single exposure early in pregnancy is unlikely to cause harm based on available data, but your obstetrician should be informed so they can monitor your pregnancy with appropriate ultrasounds and testing.

GLP-1 Medications and Reproductive Planning: What the Evidence Shows

Clinical trials for semaglutide and tirzepatide included only non-pregnant adults, so direct pregnancy outcome data does not exist. However, retrospective reports and case series from patients who conceived while on GLP-1 therapy have not documented a clear pattern of birth defects or miscarriage. This absence of harm signals does not mean the medication is safe—it reflects incomplete information rather than confirmed safety.

Weight loss itself improves fertility and pregnancy outcomes in people with obesity, including lower rates of gestational diabetes and preeclampsia. This creates a clinical dilemma: stopping semaglutide may slow weight loss progress, but continuing it during pregnancy lacks safety validation. The solution is planning: work with your healthcare provider to reach a stable weight on semaglutide before conception, then transition to non-pharmacological weight maintenance during pregnancy.

Tirzepatide, another dual GLP-1/GIP receptor agonist offered at PlexusDx, carries the same pregnancy precautions as semaglutide. Neither medication should be initiated during pregnancy or while breastfeeding, as safety data remain insufficient.

Preparing for Pregnancy While on Weight Loss Treatment

If you are taking semaglutide or another GLP-1 medication and planning to conceive, discuss your timeline with your prescriber at least six months in advance. This allows time to optimize your current weight, stabilize your metabolism, and develop sustainable eating and exercise habits that will carry you through pregnancy without medication support. Many patients find that the behavioral changes they make while on GLP-1 therapy—improved portion control, reduced cravings, and consistent activity—persist after stopping the medication.

During the pre-conception phase, PlexusDx supports personalized optimization through the Precision Peptide Genetic Test, which maps how your unique genetics influence appetite, metabolism, and weight regulation across 14 pathways. Understanding your genetic predispositions to hunger hormones (GLP1R, GIPR variants), fat deposition (FTO, MC4R variants), and satiety responses helps you and your provider build a sustainable post-medication plan before pregnancy arrives.

Pregnancy weight gain is normal and necessary; the goal is to enter pregnancy at a stable, healthy weight established on treatment, then allow natural gestational weight gain to proceed. Restarting semaglutide after pregnancy and postpartum recovery (typically 6–12 weeks postpartum, longer if breastfeeding) is safe and has been studied in observational data.

Non-Medication Weight Management During Pregnancy and Postpartum

Pregnancy requires a shift from pharmacological to behavioral and nutritional weight management. Working with a maternal-fetal medicine specialist and registered dietitian, you can focus on adequate calorie intake for fetal growth, micronutrient sufficiency, and safe exercise—typically 150 minutes of moderate activity per week unless medically contraindicated. Many structural habits formed during GLP-1 treatment (mindful eating, portion awareness, consistent physical activity) remain effective without the medication.

Postpartum weight loss is influenced by breastfeeding, which burns 300–500 additional calories daily, and the natural reduction in blood volume and fluid after delivery. If you breastfeed, resuming semaglutide is generally safe after establishing stable milk supply (around 6–8 weeks postpartum), though discussion with your obstetrician and baby's pediatrician is essential. If not breastfeeding, you may restart GLP-1 treatment sooner. PlexusDx compounded semaglutide injection starts at $149 per month and can resume as part of a comprehensive postpartum weight loss plan tailored to your genetic and metabolic profile.

PlexusDx Support for Your Fertility and Pregnancy Journey

PlexusDx does not provide obstetric care but partners with your primary care and obstetric teams to ensure safe, coordinated weight management before, during, and after pregnancy. All medications are compounded by licensed 503A pharmacies and require ongoing provider oversight—critical when your health status changes due to pregnancy. HSA and FSA accounts are eligible for PlexusDx services, reducing out-of-pocket costs for pre-conception weight optimization.

The Precision Peptide Genetic Test ($99 add-on after your first month of treatment) reveals your inherited variations in appetite-regulating genes and metabolic pathways. This data is especially valuable when planning pregnancy, as it helps your team design a post-medication lifestyle plan aligned with your biology. Understanding whether you have genetic variants linked to heightened GLP1R sensitivity, stronger hunger drive from MC4R pathways, or increased fat deposition from FTO variants enables more precise, sustainable behavioral strategies during pregnancy.

PlexusDx serves all 50 states with no insurance requirement and no membership fees, making personalized weight loss accessible before conception. If you are ready to start semaglutide or another GLP-1 therapy as part of your fertility planning, PlexusDx compounded semaglutide injection (starting at $149 per month) offers a cost-effective entry point. Your dose may need to go up during your treatment journey. Your price won't.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take semaglutide while trying to get pregnant?

Semaglutide is not recommended during pregnancy, but you may take it while actively trying to conceive. Most providers recommend stopping semaglutide at least three months before conception to allow the medication to fully clear and your metabolism to stabilize. Discuss your conception timeline with your PlexusDx provider and obstetrician to plan the optimal window for discontinuation.

What if I become pregnant while on semaglutide?

Stop semaglutide immediately and inform your obstetrician. A single exposure early in pregnancy is unlikely to cause harm based on available data, but your pregnancy will need appropriate monitoring. Do not resume semaglutide during pregnancy or immediately postpartum if breastfeeding. Your care team will advise when it is safe to restart after delivery.

Does PlexusDx help with pregnancy planning and weight loss?

Yes. PlexusDx offers compounded semaglutide injection (starting at $149/month) and personalized support through the Precision Peptide Genetic Test to help you optimize weight before conception. All services are available in all 50 states with no insurance requirement. Your prescriber will coordinate with your obstetrician to ensure safe timing around your pregnancy goals.

Is it safe to restart semaglutide after pregnancy?

Restarting semaglutide postpartum is generally safe, typically 6–12 weeks after delivery if you are not breastfeeding. If breastfeeding, discuss timing with your pediatrician and obstetrician, as reintroduction may occur around 6–8 weeks once milk supply is stable. PlexusDx can support your postpartum weight loss plan with compounded options starting at $149/month.

How does the Precision Peptide Genetic Test help with pregnancy planning?

The Precision Peptide Genetic Test ($99 add-on) maps 14 metabolic pathways and 49 peptides, including variants in GLP1R, GIPR, FTO, and MC4R genes. Understanding your genetic predispositions to hunger, satiety, and fat storage helps PlexusDx and your team design sustainable lifestyle strategies for the post-medication phase of pregnancy, so weight loss habits persist without pharmacotherapy.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves